BLA 761092 · Chiesi USA INC
Revcovi
Elapegademase-Lvlr · Injection
NovelOrphanLast checked: Nov 20, 2026Latest source record: Dec 5, 2020 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2018
Oct 5, 2018
Approved uses
n/a
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
No approvals could be loaded from Drugs@FDA just now.
Clinical trials
Interventional ClinicalTrials.gov studies with "Elapegademase" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Revcovi (Elapegademase-Lvlr)
2024 spending
$40.0M
Beneficiaries
n/a
98 claims
Per beneficiary
n/a
$8,612.24 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $14,242,374 |
| 2023 | $28,107,616 |
| 2024 | $39,969,417 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Chiesi USA INC
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.